<DOC>
	<DOC>NCT00302471</DOC>
	<brief_summary>This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.</brief_summary>
	<brief_title>MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Eligible patients must have: Prostate cancer Bone metastases without symptoms Lack of response to hormone therapy as evidenced by a rising PSA or clinical progression Prostate cancerrelated bone pain Previously received bisphosphonate therapy (e.g. zoledronate) Received any investigational treatment within the last 30 days</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>